We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Sandoz Subsidiary Called Out for Contamination Risk
Sandoz Subsidiary Called Out for Contamination Risk
The FDA cited Fougera Pharmaceuticals’ facility in Hicksville, New York, serving the Sandoz subsidiary a Form 483 for failing to follow procedures designed to prevent contamination of its drug products.